Curis, Inc. (CRIS)
CRISNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$0.6490
-0.0487 (-6.98%) today
Regular session, Nov 10, 3:59 PM ET
- Market cap
- $4.36m
- P/E
- –
- EPS, last 4 quarters
- $-48.82
- Dividend yield
- –
- Day range
- $0.5500 to $0.6600
- 52-week range
- $0.3250 to $28.40
- Average volume
- 4.86m
- Previous close
- $0.6977
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $43.00, +6525.6% from here
Earnings
next estimate $-2.29Next report Nov 12, 2026
Sep 2025
+21.0%
Dec 2025
+15.3%
Mar 2026
-557.9%
Jun 2026
+29.5%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $3.18m | $1.14m | – | – |
| Gross profit | $3.16m | $1.14m | – | – |
| Operating income | -$6.92m | $19.62m | -$11.52m | -$9.94m |
| Net income | -$7.73m | $19.36m | -$24.20m | -$8.58m |
News
8 latest- Curis, Inc. Receives Nasdaq Delist Determination Letter Following Minimum $1.00 Bid Price DeficiencyFintel · 4 days ago
- Curis Prices $5.6 Million Offering Of Shares And Warrants; Stock Up RTTNews · Aug 13, 2026
- Curis (CRIS) Q1 2026 Earnings Call TranscriptThe Motley Fool · Jun 2, 2026
- Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue EstimatesZacks · May 7, 2026
- Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue EstimatesZacks · Apr 28, 2026
- Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?Zacks · Apr 15, 2026
- Curis (CRIS) Q4 2025 Earnings Call TranscriptThe Motley Fool · Mar 19, 2026
- After-Hours Gainers: Biotech Stocks Climb On Data Anticipation And Momentum Buying RTTNews · Dec 10, 2025
The company
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL).
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- curis.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.